This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2018 Feb;47(3):434-435.

doi: 10.1111/apt.14455.

Editorial: mitigating primary nonresponse to infliximab-are we better equipped now?

D Sawbridge¹, S Subramanian¹

Affiliations

PMID: 29314136
DOI: 10.1111/apt.14455

Editorial

Editorial: mitigating primary nonresponse to infliximab-are we better equipped now?

D Sawbridge et al. Aliment Pharmacol Ther. 2018 Feb.

. 2018 Feb;47(3):434-435.

doi: 10.1111/apt.14455.

Authors

D Sawbridge¹, S Subramanian¹

Affiliation

¹ Royal Liverpool University Hospital, Liverpool, UK.

PMID: 29314136
DOI: 10.1111/apt.14455

No abstract available

PubMed Disclaimer

Comment on

Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.
Bar-Yoseph H, Levhar N, Selinger L, Manor U, Yavzori M, Picard O, Fudim E, Kopylov U, Eliakim R, Ben-Horin S, Chowers Y, Ungar B. Bar-Yoseph H, et al. Aliment Pharmacol Ther. 2018 Jan;47(2):212-218. doi: 10.1111/apt.14410. Epub 2017 Nov 9. Aliment Pharmacol Ther. 2018. PMID: 29124774

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations